文献速递肝病消化道肿瘤与早癌

ARID2 在人肝细胞癌细胞中调节 DNA 损伤应答

ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.
PubMed 文献 · J Hepatol · 2017-02-24

本研究用 CRISPR/Cas9 建立 ARID2 敲除的人肝细胞癌(HCC)细胞系,发现敲除后紫外线应答基因受负调控、细胞对紫外线敏感,且 XPG 不能聚集导致核苷酸切除修复(NER)受损,公共数据验证体内外分子变化一致,ARID2 突变亚型体细胞突变数更多。

要点

  • ARID2 敲除的 HCC 细胞紫外线应答基因受负调控并对紫外线敏感。
  • ARID2 缺失因 XPG 无法聚集而削弱紫外线及苯并[a]芘、FeCl3 所致 DNA 损伤的 NER。
  • 多种癌症中 ARID2 突变亚型的体细胞突变数高于 ARID2 野生型。

核心结论

  • ARID2 敲除可通过抑制 XPG 募集破坏 NER 过程,导致对致癌物易感并可能发生超突变,对携带 ARID2 突变的癌症有治疗靶点意义。

研究设计与样本

  • 研究用 CRISPR/Cas9 系统建立 ARID2 敲除的人 HCC 细胞系,并分析基因表达谱与生物学功能。

主要发现

  • 生物信息学分析提示 ARID2 敲除细胞中紫外线应答基因受负调控,且这些细胞对紫外线照射敏感。
  • ARID2 缺失削弱了紫外线以及已知 HCC 致癌物苯并[a]芘和 FeCl3 所致 DNA 损伤位点的核苷酸切除修复(NER),因为 XPG 在无 ARID2 时不能聚集。
  • 利用大型公共数据集验证,ARID2 敲除在体外与体内环境中可导致相似的分子变化。
  • 在包括 HCC 在内的多种癌症中,ARID2 突变亚型的体细胞突变数高于 ARID2 野生型。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recent genomic studies have identified frequent mutations of AT-rich interactive domain 2 (ARID2) in hepatocellular carcinoma (HCC), but it is not still understood how ARID2 exhibits tumor suppressor activities. METHODS: We established the ARID2 knockout human HCC cell lines by using CRISPR/Cas9 system, and investigated the gene expression profiles and biological functions. RESULTS: Bioinformatic analysis indicated that UV-response genes were negatively regulated in the ARID2 knockout cells, and they were sensitized to UV irradiation. ARID2 depletion attenuated nucleotide excision repair (NER) of DNA damage sites introduced by exposure to UV as well as chemical compounds known as carcinogens for HCC, benzo[a]pyrene and FeCl3, since xeroderma pigmentosum complementation group G (XPG) could not accumulate without ARID2. By using large-scale public data sets, we validated that ARID2 knockout could lead to similar molecular changes between in vitro and in vivo settings. A higher number of somatic mutations in the ARID2-mutated subtypes than that in the ARID2 wild-type across various types of cancers including HCC was observed. CONCLUSIONS: We provide evidence that ARID2 knockout could contribute to disruption of NER process through inhibiting the recruitment of XPG, resulting in susceptibility to carcinogens and potential hypermutation. These findings have implications for therapeutic targets in cancers harboring ARID2 mutations. LAY SUMMARY: Recent genomic studies have identified frequent mutations of ARID2, a component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex, in hepatocellular carcinoma, but it is not still understood how ARID2 exhibits tumor suppressor activities. In current study, we provided evidence that ARID2 knockout could contribute to disruption of DNA repair process, resulting in susceptibility to carcinogens and potential hypermutation. These findings have far-reaching implications for therapeutic targets in cancers harboring ARID2 mutations.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Oba A, Shimada S, Akiyama Y, et al. ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. J Hepatol. 2017. PMID: 28238438. doi:10.1016/j.jhep.2016.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。